Recurrent Breast Cancer Completed Phase 2 Trials for Capecitabine (DB01101)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00068588GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast CancerTreatment
NCT00077363Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast CancerTreatment